捷克和斯洛伐克儿童经10价或13价肺炎球菌结合疫苗基础免疫后接种13价肺炎球菌结合疫苗加强剂的免疫原性与安全性
两项在捷克和斯洛伐克开展的3期开放标签多中心研究,评估经PHiD-CV或PCV13基础免疫的儿童接种PCV13加强剂后的免疫原性与安全性。结果显示,经2剂或3剂PHiD-CV基础免疫的儿童对血清型19A的OPA滴度非劣于PCV13基础免疫组,对多数其他疫苗血清型也观察到非劣效且持久的免疫应答,两项研究均未发现安全性问题。
要点
- 经2剂或3剂PHiD-CV基础免疫的儿童接种PCV13加强剂后,对血清型19A的IgG和OPA免疫应答非劣于PCV13基础免疫组。
- 经PHiD-CV基础免疫的儿童接种PCV13加强剂后,对多数其他疫苗血清型也观察到非劣效且持久的免疫应答。
- 两项研究均未发现安全性问题,结果提示两种疫苗在安全性和免疫原性方面可互换,PCV13可用于混合接种程序的加强剂。
核心结论
- 经2剂或3剂PHiD-CV或PCV13基础免疫的儿童接种PCV13加强剂后,观察到稳健的IgG和OPA免疫应答,包括对PHiD-CV未包含的血清型;结果提示两种疫苗在安全性和免疫原性方面可互换,PCV13可用于混合接种程序的加强剂。
研究设计与样本
- 两项3期、开放标签、多中心研究,评估经PHiD-CV或PCV13基础免疫的儿童接种PCV13加强剂的免疫原性与安全性。
- 捷克共和国:12-15月龄儿童经3剂PHiD-CV或PCV13基础免疫后接种PCV13加强剂;斯洛伐克:11-12月龄儿童经2剂PHiD-CV或PCV13基础免疫后接种PCV13。
- 捷克共和国纳入98名受试者,斯洛伐克纳入89名受试者。
- 通过酶联免疫吸附试验评估血清IgG浓度,通过调理吞噬试验(OPA)评估功能性抗体,时间点为加强前及加强后1个月和12个月。
- 主要目的为评估加强后1个月时PHiD-CV基础免疫组对血清型19A的OPA滴度相对于PCV13基础免疫组的非劣效性。
主要发现
- PCV13加强剂接种后1个月,经2剂或3剂PHiD-CV基础免疫的受试者对血清型19A的IgG和OPA免疫应答非劣于经PCV13基础免疫的受试者。
- 经PHiD-CV基础免疫的受试者接种PCV13加强剂后,对多数其他疫苗血清型也观察到非劣效且持久的免疫应答。
- 两项研究均未提出安全性问题。
关键数值与推荐
- 主要终点:加强后1个月时,PHiD-CV基础免疫组对血清型19A的OPA滴度相对于PCV13基础免疫组的非劣效性,结果为非劣效。
- 经2剂或3剂PHiD-CV基础免疫的受试者接种PCV13加强剂后1个月,对血清型19A的IgG和OPA免疫应答非劣于PCV13基础免疫组。
临床怎么用
- 作者认为,这些结果提示两种疫苗在安全性和免疫原性方面可互换,PCV13可在混合接种程序中用作加强剂。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although both the 13-valent pneumococcal conjugate vaccine (PCV13) and the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) are widely used, it is unclear how interchangeable they are in terms of immunogenicity. METHODS: Two phase 3, open-label, multicenter studies were conducted to assess the immunogenicity and safety of a booster dose of PCV13 in children primed with PHiD-CV or PCV13. In the Czech Republic, 12-15-month-old children received a PCV13 booster after 3-dose priming with either PHiD-CV or PCV13. In Slovakia, 11-12-month-old children received PCV13 following 2-dose priming with either PHiD-CV or PCV13. Serum IgG concentrations were assessed by enzyme-linked immunosorbent assay and functional antibodies were assessed by opsonophagocytic assay (OPA) before the booster and at 1 and 12months afterward. The primary objective of these studies was to assess non-inferiority of OPA titers for serotype 19A in PHiD-CV-primed subjects compared to those in PCV13-primed children 1month post-booster. RESULTS: A total of 98 subjects in the Czech Republic and 89 subjects in Slovakia were included. One month after the PCV13 booster dose, the IgG and OPA immune responses to serotype 19A in subjects primed with 2 or 3 doses of PHiD-CV were non-inferior to those in subjects primed with PCV13. Non-inferior and persistent immune responses to most other vaccine serotypes were also observed after the PCV13 booster in PHiD-CV-primed subjects. No safety issues were raised in either study. CONCLUSIONS: Overall, robust IgG and OPA immunological responses were observed after booster vaccination with PCV13 in children primed with 2 or 3 doses of PHiD-CV or PCV13, including for serotypes not included in PHiD-CV. These results suggest that these vaccines are interchangeable in terms of safety and immunogenicity and that PCV13 can be used as a booster in the context of mixed schedules. (EudraCT numbers: 2012-005366-35 and 2012-005367-27).
引用
- Urbancikova I, Prymula R, Goldblatt D, et al. Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia. Vaccine. 2017. PMID: 28797727. doi:10.1016/j.vaccine.2017.07.103
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。